TABLE 4.

Patients’ response to olaparib

Patient	Original histology report	2021 WHO classification	Overall best response	Number of cycles completed	Days on treatment	Months on treatment	Progression-free survival (months)	Overall survival (months)
1	Anaplastic Astrocytoma	3	SD	10a	278a	9.3	5.5	10.9+
2	Anaplastic Astrocytoma	4	PD	2	56	1.9	1.8	9.1
3	Low-grade astrocytoma/glioma	2	SD	12	339	11.3	11.3	12.5+
4	Infiltrating glioma with astrocytic phenotype	4	PD	2	54	1.8	1.8	13.8
5	Anaplastic Astrocytoma	3	PD	2	56	1.9	1.9	32.1+
6	Infiltrating Astrocytoma	2	PD	2	55	1.8	1.8	8.3
7	Anaplastic oligodendroglioma	3	SD	5	149	5	4.9	31.5+
8	Diffuse astrocytoma	2	SD	8	224	7.5	7.4	20.7
9	Glioblastoma	4	SD	4	105	3.5	2.8	16.6
10	Diffuse astrocytoma	2	SD	14	364	12.1	12.1	29.5
11	Glioblastoma	4	PD	2	57	1.9	1.9	3.2+
12	Anaplastic Astrocytoma	3	SD	10	279	9.3	9.2	10.9+
13	Oligodendroglioma	2	SD	4	110	3.7	3.6	19.9
14	Oligodendroglioma	2	SD	5	120	4.0	4	9.1+
15	Glioblastoma	4	PD	2	54	1.8	1.8	26.1+

NOTE: PFS defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. OS calculated from initiation of treatment to date of death or last known date of contact. + = alive or lost to follow-up.

^aResults of review of patient's MRIs by CTEP-appointed independent neuroradiologist demonstrated progressive disease at end of cycle 6 (day 166 of study). Patient was treated for four additional cycles after progression.